140 related articles for article (PubMed ID: 30446274)
1. Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
Kotoula V; Lakis S; Tikas I; Giannoulatou E; Lazaridis G; Papadopoulou K; Manoussou K; Efstratiou I; Papanikolaou A; Fostira F; Vlachos I; Tarlatzis B; Fountzilas G
Gynecol Oncol; 2019 Feb; 152(2):375-386. PubMed ID: 30446274
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
3. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
[TBL] [Abstract][Full Text] [Related]
5. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
6. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
8. Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in
Eoh KJ; Park HS; Park JS; Lee ST; Han JW; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Anticancer Res; 2018 Dec; 38(12):6947-6953. PubMed ID: 30504414
[TBL] [Abstract][Full Text] [Related]
9. Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
Fountzilas G; Psyrri A; Giannoulatou E; Tikas I; Manousou K; Rontogianni D; Ciuleanu E; Ciuleanu T; Resiga L; Zaramboukas T; Papadopoulou K; Bobos M; Chrisafi S; Tsolaki E; Markou K; Giotakis E; Koutras A; Psoma E; Kalogera-Fountzila A; Skondra M; Bamia C; Pectasides D; Kotoula V
Int J Cancer; 2018 Jan; 142(1):66-80. PubMed ID: 28857155
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
11. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
13. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
14. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A
Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239
[TBL] [Abstract][Full Text] [Related]
15. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
16. Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
Rechsteiner M; Dedes K; Fink D; Pestalozzi B; Sobottka B; Moch H; Wild P; Varga Z
J Cancer Res Clin Oncol; 2018 May; 144(5):865-874. PubMed ID: 29453630
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
18. The fate of BRCA1-related germline mutations in triple-negative breast tumors.
Kotoula V; Fostira F; Papadopoulou K; Apostolou P; Tsolaki E; Lazaridis G; Manoussou K; Zagouri F; Pectasides D; Vlachos I; Tikas I; Lakis S; Konstantopoulou I; Pentheroudakis G; Gogas H; Papakostas P; Christodoulou C; Bafaloukos D; Razis E; Karavasilis V; Bamias C; Yannoukakos D; Fountzilas G
Am J Cancer Res; 2017; 7(1):98-114. PubMed ID: 28123851
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
Kotoula V; Papadopoulou K; Tikas I; Fostira F; Vrettou E; Chrisafi S; Fountzilas E; Koliou GA; Apostolou P; Papazisis K; Zaramboukas T; Asimaki-Vlachopoulou A; Miliaras S; Ananiadis A; Poulios C; Natsiopoulos I; Tsiftsoglou A; Demiri E; Fountzilas G
Breast Cancer; 2021 Nov; 28(6):1367-1382. PubMed ID: 34304347
[TBL] [Abstract][Full Text] [Related]
20. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
